Docs Who Lift Zepbound vs Wegovy trial and compounded GLP-1s
9 snips
Dec 9, 2024 The podcast dives into the results of the Surmount 5 trial, comparing Zepbound and Wegovy for weight loss. The discussion highlights the benefits of these medications, including cardiovascular effects and safety profiles. A fascinating study on GLP-1 medications revealing reduced alcohol consumption adds an intriguing angle. The risks of misusing compounded GLP-1s are also examined, drawing attention to patient safety and regulatory issues. Finally, there’s a lighthearted critique of societal attitudes towards obesity treatment and the role of big pharma.
AI Snips
Chapters
Transcript
Episode notes
Tirzepatide vs. Semaglutide for Weight Loss
- Tirzepatide (brand name Zepbound) outperforms semaglutide (Wegovy) for weight loss in individuals with obesity.
- The discussion also covers compounded GLP-1s and FDA's stance on them.
Obesity with Type 2 Diabetes and Weight Loss
- Individuals with obesity and type 2 diabetes tend to lose less weight with medication, diet, exercise, or surgery.
- A prior study showed tirzepatide resulted in greater weight loss and A1C reduction than semaglutide in this population.
Surmount 5 Top-Line Results
- Surmount 5, a 72-week open-label trial, compared tirzepatide and semaglutide for obesity with related disorders (excluding type 2 diabetes).
- Tirzepatide resulted in an average of 20% weight loss versus 14% with semaglutide, with one-third of the tirzepatide group achieving 25% weight loss.